Crinetics Pharmaceuticals (CRNX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Pipeline overview and strategic focus

• Internally developed pipeline targets endocrinology, including acromegaly, Graves' disease, obesity, and diabetes.

• First NDA submission planned for fall, aiming to transition into a fully integrated endocrine company.

• Paltusotine positioned as a next-generation therapy for acromegaly, with rapid dose titration and oral administration.

• Atumelnant shows remarkable efficacy in Cushing's and CAH, normalizing key biomarkers quickly.

• Hyperparathyroidism program targets primary, secondary, and tertiary forms, with phase I trials expected to start in 2025.

Community engagement and commercial strategy

• Deep integration with the endocrine community, focusing on education and guideline development.

• Holistic approach includes patient education, improving access, and supporting consensus standards.

• Commercial strategy remains unchanged despite CCO departure; focus on expanding reach beyond centers of excellence.

• Identifying and activating thousands of untreated or inadequately controlled patients is a key priority.

• Building relationships with patient groups to empower advocacy and improve care standards.

Clinical development and trial design

• Paltusotine's phase 3 data supports rapid symptom control and potential for broader use in acromegaly.

• Placebo-controlled phase 3 trials planned for carcinoid syndrome, with rescue criteria to ensure patient safety.

• Atumelnant trials for CAH and Cushing's will likely be placebo-controlled, with endpoints focused on biomarker normalization and glucocorticoid reduction.

• Cushing's and acromegaly trials benefit from overlapping clinical centers and expertise.

• Phase I data for hyperparathyroidism program expected in 2025, with PK data anticipated the same year.